SGC-CBP30 is a potent and selective inhibitor of the CREB-binding protein (CBP) and its paralog p300, which are histone acetyltransferases involved in the regulation of gene expression. It is widely used in epigenetic research to probe the biological roles of CBP/p300 in cellular processes such as differentiation, proliferation, and apoptosis. Due to its ability to modulate acetylation-dependent signaling pathways, SGC-CBP30 has shown promise in studies related to cancer, particularly hematological malignancies like multiple myeloma and leukemia, where CBP/p300 activity contributes to oncogene expression. It is also employed in inflammation and immune response research, given the role of CBP/p300 in NF-κB signaling. Its selectivity makes it a valuable tool compound for validating CBP/p300 as a therapeutic target without significant off-target effects on other acetyltransferases.